Universal Beteiligungs und Servicegesellschaft mbH Trims Stake in Cencora, Inc. (NYSE:COR)

Universal Beteiligungs und Servicegesellschaft mbH lowered its stake in shares of Cencora, Inc. (NYSE:COR - Free Report) by 4.7% in the first quarter, according to its most recent 13F filing with the SEC. The fund owned 163,921 shares of the company's stock after selling 8,111 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.08% of Cencora worth $45,585,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in COR. Cornerstone Planning Group LLC boosted its stake in shares of Cencora by 106.7% in the 1st quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock worth $26,000 after buying an additional 48 shares during the last quarter. Hoey Investments Inc. purchased a new position in shares of Cencora in the 1st quarter worth approximately $28,000. Banque Transatlantique SA purchased a new position in shares of Cencora in the 4th quarter worth approximately $29,000. Vermillion Wealth Management Inc. purchased a new position in shares of Cencora in the 4th quarter worth approximately $38,000. Finally, Golden State Wealth Management LLC boosted its stake in shares of Cencora by 157.6% in the 1st quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock worth $47,000 after buying an additional 104 shares during the last quarter. Institutional investors and hedge funds own 97.52% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. Citigroup boosted their target price on Cencora from $330.00 to $355.00 and gave the stock a "buy" rating in a research note on Thursday, May 8th. Morgan Stanley set a $330.00 target price on Cencora and gave the stock an "equal weight" rating in a research note on Wednesday, July 16th. UBS Group lifted their price target on shares of Cencora from $298.00 to $335.00 and gave the stock a "buy" rating in a report on Tuesday, April 29th. Robert W. Baird lifted their price target on shares of Cencora from $314.00 to $350.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Finally, Wells Fargo & Company raised shares of Cencora from an "equal weight" rating to an "overweight" rating and lifted their price target for the stock from $274.00 to $337.00 in a report on Tuesday, June 3rd. Three research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $309.83.

Cencora Stock Performance

COR stock traded down $0.28 during midday trading on Friday, reaching $290.17. 785,267 shares of the company's stock traded hands, compared to its average volume of 1,072,635. The company has a 50-day moving average price of $293.31 and a two-hundred day moving average price of $274.53. The company has a debt-to-equity ratio of 6.01, a quick ratio of 0.52 and a current ratio of 0.87. Cencora, Inc. has a 52 week low of $218.65 and a 52 week high of $309.35. The firm has a market capitalization of $56.24 billion, a PE ratio of 33.66, a price-to-earnings-growth ratio of 1.44 and a beta of 0.57.

Cencora (NYSE:COR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $4.42 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.07 by $0.35. Cencora had a net margin of 0.55% and a return on equity of 344.71%. The business had revenue of $75.50 billion for the quarter, compared to analysts' expectations of $75.41 billion. During the same quarter in the previous year, the firm posted $3.80 EPS. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. As a group, equities analysts anticipate that Cencora, Inc. will post 15.37 EPS for the current year.

Cencora Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, June 2nd. Shareholders of record on Friday, May 16th were issued a dividend of $0.55 per share. The ex-dividend date was Friday, May 16th. This represents a $2.20 dividend on an annualized basis and a yield of 0.76%. Cencora's payout ratio is 25.52%.

Insiders Place Their Bets

In other news, Chairman Steven H. Collis sold 14,578 shares of the business's stock in a transaction on Tuesday, July 22nd. The shares were sold at an average price of $292.67, for a total transaction of $4,266,543.26. Following the completion of the transaction, the chairman directly owned 309,913 shares in the company, valued at $90,702,237.71. The trade was a 4.49% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Robert P. Mauch sold 4,968 shares of the business's stock in a transaction on Friday, July 18th. The shares were sold at an average price of $294.11, for a total transaction of $1,461,138.48. Following the transaction, the chief executive officer owned 42,351 shares of the company's stock, valued at $12,455,852.61. This trade represents a 10.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 34,125 shares of company stock worth $9,993,789 in the last three months. Insiders own 10.80% of the company's stock.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.